Literature DB >> 16115924

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Masanori Onda1, Mark Willingham, Satoshi Nagata, Tapan K Bera, Richard Beers, Mitchell Ho, Raffit Hassan, Robert J Kreitman, Ira Pastan.   

Abstract

PURPOSE: Mesothelin is a cell surface protein that is highly expressed in some malignant tumors, and is a promising target for immunotherapy. Recent data suggests that mesothelin is an adhesive protein and may have a role in the metastases of ovarian cancer. Although a few monoclonal antibodies (MAb) to mesothelin have been produced, they have limitations for the study of expression of native mesothelin because of their low affinity or reactivity only with denatured mesothelin protein. We have produced novel MAbs to mesothelin to help study mesothelin function and to develop improved diagnosis and immunotherapy of mesothelin-expressing tumors. EXPERIMENTAL
DESIGN: Mesothelin-deficient mice were immunized with plasmid cDNA encoding mesothelin, and boosted with a mesothelin-rabbit IgG Fc fusion protein prior to cell fusion. Hybridomas were screened by an ELISA using plates coated with mesothelin-Fc protein.
RESULTS: Seventeen hybridomas producing anti-mesothelin antibodies were established and shown to react with two epitopes on mesothelin. One group reacts with the same epitope as the low affinity antibody K1 that was originally used to identify mesothelin. The other is a new group that reacts with a new epitope. One antibody from each group was chosen for further study and shown to react strongly on ELISA, on immunohistochemistry, and by fluorescence-activated cell sorting on living cells.
CONCLUSION: Our two newly established MAbs, MN and MB, have different and useful properties compared with current antibodies used for the detection of mesothelin by immunohistochemistry, fluorescence-activated cell sorting, ELISA, and Western blotting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115924     DOI: 10.1158/1078-0432.CCR-05-0578

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Diagnostic tumor marker of asbestos-related mesothelioma.

Authors:  Okio Hino; Masahiro Maeda
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

Review 2.  Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

Authors:  Mitchell Ho
Journal:  BioDrugs       Date:  2011-10-01       Impact factor: 5.807

3.  Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries.

Authors:  Lorenz Waldmeier; Ina Hellmann; Chantal K Gutknecht; Fabian I Wolter; Skylar C Cook; Sai T Reddy; Ulf Grawunder; Roger R Beerli
Journal:  MAbs       Date:  2016-03-17       Impact factor: 5.857

4.  In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.

Authors:  Kevin Hollevoet; Emily Mason-Osann; Xiu-fen Liu; Sabine Imhof-Jung; Gerhard Niederfellner; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2014-06-13       Impact factor: 6.261

5.  Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.

Authors:  Kevin Hollevoet; Antonella Antignani; David J Fitzgerald; Ira Pastan
Journal:  J Immunother       Date:  2014-01       Impact factor: 4.456

6.  Expression of POTE protein in human testis detected by novel monoclonal antibodies.

Authors:  Tomoko Ise; Sudipto Das; Satoshi Nagata; Hiroshi Maeda; Yoomi Lee; Masanori Onda; Miriam R Anver; Tapan K Bera; Ira Pastan
Journal:  Biochem Biophys Res Commun       Date:  2007-11-09       Impact factor: 3.575

7.  Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Authors:  Prince Awuah; Tapan K Bera; Messan Folivi; Oleg Chertov; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

8.  Mesothelin expression in the leptomeninges and meningiomas.

Authors:  Mahlon D Johnson; Fran Vito; Mary J O'Connell
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

9.  Mesothelin as a potential therapeutic target in human cholangiocarcinoma.

Authors:  Liping Yu; Mingqian Feng; Heungnam Kim; Yen Phung; David E Kleiner; Gregory J Gores; Min Qian; Xin Wei Wang; Mitchell Ho
Journal:  J Cancer       Date:  2010-10-01       Impact factor: 4.207

10.  A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.

Authors:  Zhewei Tang; Mingqian Feng; Wei Gao; Yen Phung; Weizao Chen; Amit Chaudhary; Brad St Croix; Min Qian; Dimiter S Dimitrov; Mitchell Ho
Journal:  Mol Cancer Ther       Date:  2013-01-31       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.